Clinical Evidence: What the Research Shows for Both Treatments
Mounjaro vs Wegovy: Understanding the Clinical Trial Evidence
When comparing Mounjaro and Wegovy weight loss results, it's essential to examine the robust clinical evidence supporting both treatments. In clinical trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks in the landmark STEP 1 study (Wilding et al., NEJM, 2021). The STEP 3 trial demonstrated around clinically studied weight loss when combined with intensive behavioural therapy, whilst STEP 5 showed sustained results of approximately 15.2% at two years. Mounjaro's SURMOUNT trials revealed impressive outcomes, with the highest dose achieving significant weight reductions in patients following a reduced-calorie diet and increased physical activity.
Both medications represent innovative advances in prescription weight management, though they cannot be directly compared due to different trial designs, populations, and endpoints. Wegovy contains semaglutide, a GLP-1 receptor agonist, whilst Mounjaro contains tirzepatide, a dual GIP and GLP-1 receptor agonist. The SELECT cardiovascular outcomes trial showed Wegovy reduced major cardiovascular events by 20% in adults with established cardiovascular disease. Understanding these nuances helps patients and prescribers determine which treatment aligns with individual health goals and medical circumstances.
Mounjaro Wegovy Pricing: Complete UK Cost Comparison
EverydayMeds offers transparent pricing for both Mounjaro and Wegovy, ensuring patients understand exactly what they'll pay throughout their weight management journey. Wegovy starts at £79.99 for the 0.25mg starter dose, progressing to £94.99 for 0.5mg, £99.99 for 1mg, £139.99 for 1.7mg, and £209.99 for the 2.4mg maintenance dose. New customers benefit from discount code FIRST40 applied at checkout, whilst returning patients use code DOSE25. Our Getting Started bundles provide convenient dosing progression, such as the Intro Duo (0.25mg & 0.5mg) for £169.99 or the Progress Trio including three escalation doses for £299.99.
Mounjaro pricing follows a similar transparent structure, with both treatments requiring identical prescriber assessment and delivery processes. Our Ultimate Stability Trio provides three months of maintenance supply for patients established on their optimal dose, delivered with professional cold-chain handling. All prices include comprehensive clinical review by GPhC-registered prescribers (#9012878), next-day temperature-controlled delivery, and ongoing support throughout treatment. Both Wegovy and Mounjaro are available from EverydayMeds, with your prescriber helping determine which option suits your medical profile and weight management goals.
Wegovy vs Mounjaro: How Each Mechanism Supports Weight Loss
Understanding how Wegovy and Mounjaro work differently can help explain their respective clinical trial outcomes and practical benefits. Wegovy contains semaglutide, which mimics the GLP-1 hormone naturally produced in the intestines after eating, promoting feelings of fullness and reducing appetite through brain appetite centres. Mounjaro contains tirzepatide, which activates both GLP-1 and GIP receptors, potentially offering dual pathways for appetite regulation and glucose control. Both treatments slow gastric emptying, meaning food stays in the stomach longer, contributing to sustained satiety after smaller meals.
Clinical evidence suggests both mechanisms effectively support weight management when combined with lifestyle modifications, though individual responses may vary based on personal physiology and adherence to prescribed dosing schedules. The gradual dose escalation required for both treatments helps minimise potential gastrointestinal side effects whilst allowing the body to adapt to increased hormone activity. Your prescriber will consider factors including medical history, current medications, and weight management goals when recommending between these two evidence-based options available through EverydayMeds.
Assessment Process: Getting Prescribed Mounjaro or Wegovy
EverydayMeds streamlines access to both Mounjaro and Wegovy through a comprehensive three-minute online clinical assessment designed to gather essential medical information safely and efficiently. Our GPhC-registered prescribers (#9012878) review each application within three working days (or 24 hours with express service), ensuring every patient receives appropriate medical oversight before starting treatment. The assessment covers current health status, previous weight management attempts, existing medications, and relevant medical conditions that might influence treatment selection. Once approved, medications are dispatched via next-day delivery using specialist cold-chain logistics to maintain temperature integrity throughout transit. Patients receive clear dosing instructions, injection technique guidance, and ongoing support throughout their weight management journey with professional clinical oversight.
Storage and Practical Differences: Mounjaro vs Wegovy Convenience
Both Mounjaro and Wegovy require refrigeration at 2-8°C before first use, though they differ in room temperature stability once removed from the fridge. Wegovy offers superior travel convenience, remaining stable for up to six weeks at room temperature below 30°C, compared to Mounjaro's 21-day room temperature limit. Both treatments use pre-filled FlexTouch injection pens designed for once-weekly subcutaneous administration, typically in the thigh, abdomen, or upper arm. The dose escalation schedule is mandatory for both medications, starting at the lowest dose and gradually increasing every four weeks to minimise side effects and optimise tolerance. Patients should never skip escalation steps or increase doses faster than recommended, as this significantly increases the risk of gastrointestinal side effects and treatment discontinuation.
Real-World Mounjaro Wegovy Results: What UK Patients Experience
Beyond clinical trial data, real-world evidence provides valuable insights into how Mounjaro and Wegovy perform in typical UK healthcare settings with diverse patient populations. Post-marketing surveillance and patient registries suggest that clinical trial outcomes often translate well to everyday practice when patients adhere to prescribed dosing and maintain recommended lifestyle modifications. However, individual results vary significantly based on starting weight, adherence to diet and exercise recommendations, dose tolerance, and consistency of weekly injections. Some patients achieve results exceeding clinical trial averages, whilst others may experience more modest outcomes or require treatment adjustments.
The key to successful outcomes with either treatment lies in realistic expectations, consistent administration, and ongoing communication with prescribing healthcare providers about progress and any challenges encountered. EverydayMeds patients benefit from continuous clinical support, ensuring any questions or concerns receive prompt professional attention throughout their weight management journey. Both Wegovy and Mounjaro represent significant advances in prescription weight management, offering evidence-based options for patients who haven't achieved sustainable results through diet and exercise alone.
UK Regulatory Status: MHRA Approval and NICE Recommendations
Both Mounjaro and Wegovy hold full MHRA marketing authorisation for weight management in appropriate adult patients with BMI ≥30, or BMI ≥27 with weight-related comorbidities. Wegovy is recommended by NICE (TA875) for specialist weight management services, reflecting its established evidence base and cost-effectiveness profile. As prescription-only medicines, both treatments require proper medical assessment and ongoing clinical supervision, which EverydayMeds provides through our team of qualified prescribers. The MHRA continues monitoring both treatments for safety and efficacy, with regular updates to prescribing information based on emerging real-world evidence.
Understanding regulatory approval helps patients appreciate the rigorous evaluation process both treatments underwent before reaching UK patients, providing confidence in their safety and efficacy profiles when used appropriately. Both medications carry additional monitoring status, meaning healthcare providers report any suspected adverse reactions to support ongoing safety surveillance. This regulatory framework ensures patient safety whilst maintaining access to innovative weight management treatments for those who meet clinical criteria and can benefit from prescription intervention alongside lifestyle modifications.
Making Your Choice: Mounjaro or Wegovy Through EverydayMeds
Choosing between Mounjaro and Wegovy ultimately depends on individual medical circumstances, previous treatment responses, and practical considerations discussed with qualified prescribers. Both treatments offer compelling clinical evidence, though direct comparison isn't possible due to different trial methodologies and patient populations. EverydayMeds provides access to both options with identical professional standards, transparent pricing, and comprehensive clinical support throughout treatment. Our prescribers consider your complete medical history, current health status, and weight management goals when recommending the most appropriate option. Whether you choose Wegovy starting from £79.99 or Mounjaro with similar pricing structure, you'll receive the same high-quality clinical oversight and delivery service that has made EverydayMeds a trusted choice for UK weight management patients seeking evidence-based prescription treatments with professional medical support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
